Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Lemonade Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Lemonade Inc trades at $43.49 (market cap $3.46B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 2.6× Lemonade Inc's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Lemonade Inc for 27 Days on average.
| KYMR | LMND | |
|---|---|---|
Market Cap | $8.87B | $3.46B |
Volume | 779,107 | 1,011,472 |
Sector | Health | Financials |
52-Week High | $127.31 | $96.57 |
52-Week Low | $55.80 | $43.86 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $8.26B | $3.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lemonade (LMND) trades at $43.86, down 2.86% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company continues to show strong revenue growth, with 2025 revenue reaching $738 million and improving margins, though it remains unprofitable with a net loss of $166 million. Recent expansion into Alaska and Kentucky, along with AI-driven efficiency improvements, supports the company's path toward EBITDA profitability by late 2026.
While Lemonade shows promising growth and margin improvement, the stock faces near-term technical pressure and persistent profitability challenges. The consensus price target of $67 offers significant upside potential, but investors must weigh expansion opportunities against ongoing losses and competitive pressures in the insurtech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
